In summary, our work provides mechanistic insights into why CRC patients with wild-type KRAS and TP53 CRC respond better to anti-PD-1 treatment and highlights that MYC may be an important drug target for improving the efficacy of immunotherapy. The gene discussed is TP53; the disease is colorectal carcinoma.